ALLOAllogene Therapeutics, Inc.
2.185USD+1.16%Mkt Cap: 750.71M USDP/E: Last update: 2026-06-01

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipe…

Indicators:|

Key Statistics

Company
Market Cap750.71M USD
Enterprise Value563.15M USD
Revenue (TTM)
Gross Profit-131.96M USD
Net Income (TTM)-190.89M USD
Revenue/Share
Last Price2.185 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees150
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-2.82
PEG
EV/EBITDA-3.21
EV/Revenue
P/S
P/B1.91
EPS (TTM)-0.77
EPS (Forward)-0.77
52W Range
0.980035% of range4.460
52W High4.460 USD
52W Low0.9800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-65.25%
ROA-45.90%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-149.25M USD
CapEx (TTM)386.00K USD
FCF Margin
FCF Yield-9.32%
Net Debt-185.84M USD
Net Debt/EBITDA1.06
Balance Sheet
Debt/Equity0.28
Current Ratio9.65
Quick Ratio9.47
Book Value/Sh1.139 USD
Cash/Share0.7730 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.350 USD
Target Range3.850 USD14.00 USD
# Analysts11
Ownership
Shares Out.345.15M
Float269.64M
Insiders11.05%
Institutions52.87%
Short Interest
Short Ratio3.8d
Short % Float13.56%
Short % Out.12.25%
Shares Short42.28M
Short (prev mo.)36.38M
Technical
SMA 502.298 (-4.9%)
SMA 2001.695 (+28.9%)
Beta0.46
S&P 52W Chg27.94%
Avg Vol (30d)6.69M
Avg Vol (10d)6.60M
Technical Indicators
RSI (14)49.2
MACD-0.0476
MACD Signal-0.0699
MACD Hist.+0.0223
BB Upper2.445 USD
BB Middle2.147 USD
BB Lower1.849 USD
BB Width27.79%
ATR (14)0.1708 USD
Vol Ratio (20d)1.18x